Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
15.92
USD
|
+0.95%
|
|
-7.66%
|
+9.27%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
109.1
|
94.32
|
196.8
|
303.6
|
367.7
|
484.8
|
-
|
-
|
Enterprise Value (EV)
1 |
109.1
|
94.32
|
196.8
|
303.6
|
367.7
|
484.8
|
484.8
|
484.8
|
P/E ratio
|
-14.8
x
|
-9.96
x
|
-5.97
x
|
-5.31
x
|
-5.42
x
|
-5.5
x
|
-4.59
x
|
-5.69
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
96.2
x
|
41.4
x
|
6.78
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
96.2
x
|
41.4
x
|
6.78
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
10,252
|
10,297
|
14,919
|
21,667
|
25,238
|
30,453
|
-
|
-
|
Reference price
2 |
10.64
|
9.160
|
13.19
|
14.01
|
14.57
|
15.92
|
15.92
|
15.92
|
Announcement Date
|
3/13/20
|
2/16/21
|
3/23/22
|
3/23/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
5.041
|
11.71
|
71.52
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-6.764
|
-9.556
|
-28.36
|
-39.39
|
-66.23
|
-89.28
|
-127.2
|
-124.8
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-1,771.1%
|
-1,086.09%
|
-174.44%
|
Earnings before Tax (EBT)
1 |
-7.359
|
-9.474
|
-29.61
|
-40.37
|
-63.78
|
-83.54
|
-126.9
|
-124
|
Net income
1 |
-7.359
|
-9.474
|
-29.61
|
-40.37
|
-63.78
|
-86.43
|
-126.9
|
-124
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-1,714.63%
|
-1,083.77%
|
-173.43%
|
EPS
2 |
-0.7200
|
-0.9200
|
-2.210
|
-2.640
|
-2.690
|
-2.892
|
-3.470
|
-2.798
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/13/20
|
2/16/21
|
3/23/22
|
3/23/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1.512
|
3.529
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-12.5
|
-15.02
|
-18.86
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-5.6
|
-6.321
|
-7.508
|
-9.601
|
-10.64
|
-11.64
|
-12.55
|
-15.06
|
-18.9
|
-19.73
|
-20.92
|
-22.09
|
-23.16
|
-23.3
|
-20.25
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,531.78%
|
-660.43%
|
-
|
Earnings before Tax (EBT)
1 |
-6.027
|
-6.754
|
-7.934
|
-9.961
|
-10.89
|
-11.58
|
-11.94
|
-14.59
|
-18.4
|
-18.85
|
-20.57
|
-21.86
|
-23.07
|
-23.24
|
-20.45
|
Net income
1 |
-6.027
|
-6.754
|
-7.934
|
-9.961
|
-10.89
|
-11.58
|
-11.94
|
-14.59
|
-18.4
|
-18.85
|
-20.08
|
-21.52
|
-23.07
|
-23.22
|
-20.45
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,525.87%
|
-657.97%
|
-
|
EPS
2 |
-0.4100
|
-0.4500
|
-0.5300
|
-0.6700
|
-0.7500
|
-0.6900
|
-0.5500
|
-0.6600
|
-0.8300
|
-0.6500
|
-0.6980
|
-0.7340
|
-0.7620
|
-0.6980
|
-0.7650
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/8/21
|
3/23/22
|
5/16/22
|
8/11/22
|
11/10/22
|
3/23/23
|
5/15/23
|
8/10/23
|
11/13/23
|
3/27/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
-
|
-
|
-
|
0.1
|
0.6
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
0.85%
|
0.84%
|
Announcement Date
|
3/13/20
|
2/16/21
|
3/23/22
|
3/23/23
|
3/27/24
|
-
|
-
|
-
|
Last Close Price
15.92
USD Average target price
29.5
USD Spread / Average Target +85.30% Consensus |
1st Jan change
|
Capi.
|
---|
| +9.27% | 485M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|